What is Medi-Tate?
Medi-Tate is an Israeli-based medical technology firm specializing in the development of minimally invasive solutions for BPH. Its flagship product, the iTind treatment, represents a significant shift away from traditional surgical procedures, offering patients a more comfortable and efficient recovery process. With regulatory approvals spanning the European Union, the UK, Israel, Australia, Brazil, and the United States, the company has demonstrated a robust ability to navigate complex international medical markets. By addressing a common condition that affects millions of men globally, Medi-Tate has established a strong competitive moat through its unique, non-surgical approach to urological care.
How much funding has Medi-Tate raised?
Medi-Tate has raised a total of $2M across 1 funding round:
Private Equity
$2M
Private Equity (2015): $2M with participation from Xenia Venture Capital
Key Investors in Medi-Tate
Xenia Venture Capital
Xenia Venture Capital is a publicly traded investment firm based in Israel that specializes in high-tech and med-tech sectors, providing comprehensive support and strategic counseling to early-stage companies.
What's next for Medi-Tate?
With this major enterprise-level funding, Medi-Tate is poised to accelerate its commercialization strategy and expand its footprint in the United States market. The capital will likely be deployed toward scaling manufacturing capabilities, enhancing clinical data collection, and broadening the adoption of the iTind system among urologists. As the company transitions from a development-focused entity to a commercial-stage leader, the focus will shift toward securing deeper market penetration and exploring potential strategic partnerships to solidify its long-term growth trajectory in the global men's health sector.
See full Medi-Tate company page
